Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 11/20 | 1.00 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 1.00 |
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 1.00 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 1.00 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 1.00 |
| ▸ | ADRB3 known ✓ | P13945 | 1/20 | 1.00 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 1.00 |
| ▸ | S1PR1 known ✓ | P21453 | 1/20 | 1.00 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 1.00 |
| ▸ | HTR1D known ✓ | P28221 | 1/20 | 1.00 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 1.00 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 1.00 |
| ▸ | AGTR1 known ✓ | P30556 | 1/20 | 1.00 |
| ▸ | ADRA1B known ✓ | P35368 | 1/20 | 1.00 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 1.00 |
| ▸ | HTR5A known ✓ | P47898 | 1/20 | 1.00 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 1.00 |
| ▸ | OPRK1 known ✓ | P41145 | 10/20 | 0.98 |
| ▸ | OPRD1 known ✓ | P41143 | 1/20 | 0.98 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31621908 | 1.00 | OPRM1 (1.00) | OPRM1CHRM2CHRM4ADRA2ACHRM1 | |
| Hydrochloric Acid SCHEMBL4913782 | 0.99 | OPRM1 (0.98) | OPRM1CHRM2CHRM4ADRA2ACHRM1 | |
| SCHEMBL29519900 | 0.99 | OPRL1 (1.00) | OPRM1CHRM2CHRM4ADRA2ACHRM1 | |
| SCHEMBL4916443 | 0.99 | OPRL1 (1.00) | OPRM1CHRM2CHRM4ADRA2ACHRM1 | |
| SCHEMBL31237285 | 0.99 | OPRL1 (1.00) | OPRM1CHRM2CHRM4ADRA2ACHRM1 | |
| Hydrochloric Acid SCHEMBL4918935 | 0.93 | OPRM1 (0.87) | OPRM1CHRM2CHRM4ADRA2ACHRM1 | |
| Hydrochloric Acid SCHEMBL4909856 | 0.93 | OPRM1 (0.87) | OPRM1CHRM2CHRM4ADRA2ACHRM1 | |
| Hydrochloric Acid SCHEMBL4911001 | 0.93 | OPRL1 (0.98) | OPRM1CHRM2CHRM4ADRA2ACHRM1 | |
| Hydrochloric Acid SCHEMBL4920232 | 0.92 | OPRL1 (0.98) | OPRM1CHRM2CHRM4ADRA2ACHRM1 | |
| Hydrochloric Acid SCHEMBL4918400 | 0.92 | OPRL1 (0.98) | OPRM1CHRM2CHRM4ADRA2ACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7557088-B2 | Methods and compositions for treating conditions | NEOPRO LABS, LLC (US) | 2009-07-07 | — | — | US | claimed |
| EP-2015765-A2 | METHODS AMD COMPOSITIONS FOR TREATING CONDITIONS | Neopro Labs, LLC (US) | 2009-01-21 | — | — | EP | claimed |
| US-20080103162-A1 | Antipruritics | OYAMA TATSUYA | 2008-05-01 | — | — | US | claimed |
| US-20070259818-A1 | Methods and Compositions for Treating Conditions | NEOPRO LABS, LLC | 2007-11-08 | — | — | US | claimed |
| WO-2007112453-A2 | METHODS AMD COMPOSITIONS FOR TREATING CONDITIONS | NEOPRO LABS, LLC (US) | 2007-10-04 | — | — | WO | claimed |
| US-20060030565-A1 | Amide derivatives and nociceptin antagonists | JAPAN TOBACCO INC. | 2006-02-09 | — | — | US | claimed |
| US-20040116450-A1 | Antipruritics | NIPPON SHINYAKU CO., LTD. (JP) | 2004-06-17 | — | — | US | claimed |
| EP-1371376-A1 | ANTIPRURITICS | Nippon Shinyaku Co., Ltd. (JP) | 2003-12-17 | — | — | EP | claimed |
| US-20030055087-A1 | Amide derivatives and nociceptin antagonists | JAPAN TOBACCO INC. | 2003-03-20 | — | — | US | claimed |
| US-6410561-B1 | ANALGESICS | JAPAN TOBACCO INC. (JP) | 2002-06-25 | — | — | US | claimed |
| WO-2002047726-A2 | PHARMACEUTICAL COMPOSITION CONTAINING AN ACTIVE WITH A HEMOLYTIC ACTION AND A SURFACTANT | JAPAN TOBACCO INC. (JP) | 2002-06-20 | — | — | WO | claimed |
| EP-1072263-A1 | AMIDE DERIVATIVES AND NOCICEPTIN ANTAGONISTS | JAPAN TOBACCO INC. (JP) | 2001-01-31 | — | — | EP | claimed |
| US-9226918-B2 | Methods and compositions for treating or preventing narcotic withdrawal symptoms | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2016-01-05 | — | — | US | disclosed |
| US-20150190416-A1 | FILAGGRIN PRODUCTION PROMOTER, THERAPEUTIC AGENT FOR DISEASES ASSOCIATED WITH REDUCTION IN PRODUCTION OF FILAGGRIN, AND METHOD FOR SCREENING FOR SAID THERAPEUTIC AGENT | ASTELLAS PHARMA INC. (JP) | 2015-07-09 | — | — | US | disclosed |
| EP-2878309-A1 | FILAGGRIN PRODUCTION PROMOTER, THERAPEUTIC AGENT FOR DISEASES ASSOCIATED WITH REDUCTION IN PRODUCTION OF FILAGGRIN, AND METHOD FOR SCREENING FOR SAID THERAPEUTIC AGENT | Kyoto University (JP) | 2015-06-03 | — | — | EP | disclosed |
| EP-1491212-B1 | REMEDY FOR SLEEP DISTURBANCE | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-08-08 | — | — | EP | disclosed |
| US-20030055087-A1 | Amide derivatives and nociceptin antagonists | JAPAN TOBACCO INC. | 2003-03-20 | — | — | US | disclosed |
| US-6410561-B1 | ANALGESICS | JAPAN TOBACCO INC. (JP) | 2002-06-25 | — | — | US | disclosed |
| WO-2002047726-A2 | PHARMACEUTICAL COMPOSITION CONTAINING AN ACTIVE WITH A HEMOLYTIC ACTION AND A SURFACTANT | JAPAN TOBACCO INC. (JP) | 2002-06-20 | — | — | WO | disclosed |
| EP-1072263-A1 | AMIDE DERIVATIVES AND NOCICEPTIN ANTAGONISTS | JAPAN TOBACCO INC. (JP) | 2001-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055087-A1 | Amide derivatives and nociceptin antagonists | OPRL1, OPRD1, OPRK1 | OPRM1 4/4885CHRM2 968/4885CHRM4 1064/4885 |
| US-20080103162-A1 | Antipruritics | ITCH, NTSR1, OPRL1 | OPRM1 158/4885CHRM2 436/4885CHRM4 1048/4885 |
| US-20150190416-A1 | FILAGGRIN PRODUCTION PROMOTER, THERAPEUTIC AGENT FOR DISEASES ASSOCIATED WITH REDUCTION IN PRODUCTION OF FILAGGRIN, AND METHOD FOR SCREENING FOR SAID THERAPEUTIC AGENT | FLNA, FLNB, TRPV5 | OPRM1 4825/4885CHRM2 3390/4885CHRM4 3225/4885 |
| US-20060030565-A1 | Amide derivatives and nociceptin antagonists | OPRL1, OPRD1, OPRM1 | OPRM1 3/4885CHRM2 316/4885CHRM4 546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.